| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/28/2005 | CA2542761A1 Analgesia method |
| 04/28/2005 | CA2542757A1 Use of organic compounds |
| 04/28/2005 | CA2542755A1 Biguanide drug-containing jelly preparation |
| 04/28/2005 | CA2542753A1 Enhancing transdermal administration of hydrophilic drugs |
| 04/28/2005 | CA2542727A1 Derivatives of n-[phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics |
| 04/28/2005 | CA2542723A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
| 04/28/2005 | CA2542694A1 Compounds for dual photodiagnosis and therapy |
| 04/28/2005 | CA2542653A1 Substituted benzazoles and use thereof as inhibitors of raf kinase |
| 04/28/2005 | CA2542636A1 Muscarinic acetylcholine receptor antagonists field of the invention |
| 04/28/2005 | CA2542634A1 Disinfecting teat care compositions |
| 04/28/2005 | CA2542506A1 Pectin films prepared from gamma irradiated pectin |
| 04/28/2005 | CA2542504A1 Lipids containing omega-3 and omega-6 fatty acids |
| 04/28/2005 | CA2542440A1 Furan derivatives as ep4 receptor antagonists |
| 04/28/2005 | CA2542395A1 Treatment of arthritic conditions, chronic inflammation or pain |
| 04/28/2005 | CA2542373A1 Derivatives of n-phenyl(piperidine-2-yl)methyl benzamide, preparation method thereof and applications of same in therapeutics |
| 04/28/2005 | CA2542337A1 Cancer gene therapeutic drug |
| 04/28/2005 | CA2542335A1 Cancer gene therapeutic drug |
| 04/28/2005 | CA2542332A1 Immunomodulating compositions and uses therefor |
| 04/28/2005 | CA2542329A1 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| 04/28/2005 | CA2542327A1 Combination therapy for cancer |
| 04/28/2005 | CA2542290A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof |
| 04/28/2005 | CA2542269A1 Fusion molecules comprising antigens and mhc i or ii cytoplasmic domains |
| 04/28/2005 | CA2542128A1 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 04/28/2005 | CA2542113A1 Compositions useful as inhibitors of protein kinases |
| 04/28/2005 | CA2542076A1 Substituted tricyclic compounds as protein kinase inhibitors |
| 04/28/2005 | CA2542074A1 Methods and reagents for the treatment of immunoinflammatory disorders |
| 04/28/2005 | CA2541857A1 Combination therapy for hcv infection |
| 04/28/2005 | CA2541847A1 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| 04/28/2005 | CA2541751A1 Phenoxyether derivatives as ppar modulators |
| 04/28/2005 | CA2541509A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| 04/28/2005 | CA2541425A1 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 04/28/2005 | CA2541405A1 The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
| 04/28/2005 | CA2541402A1 Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives |
| 04/28/2005 | CA2541265A1 Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
| 04/28/2005 | CA2541264A1 Breast cancer treatment regimen |
| 04/28/2005 | CA2540861A1 Novel tetraydrospiro{piperidine-2,7' -pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-ht6 receptor -related disorders |
| 04/28/2005 | CA2540860A1 Preparation of 3-azabicyclo [3.1.0] hexane derivatives |
| 04/28/2005 | CA2540859A1 Topical compositions comprising telmesteine for treating dermatological disorders |
| 04/28/2005 | CA2540623A1 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischenic mediated central nervous system disorders or injury |
| 04/28/2005 | CA2540503A1 Transdermal no-generating agents for treating tendinopathy |
| 04/28/2005 | CA2540207A1 Substituted aryl cycloalkanol derivatives and methods of their use |
| 04/28/2005 | CA2540195A1 Amphiphilic [5:1]- and [3:3]- hexakisadducts of fullerenes |
| 04/28/2005 | CA2540191A1 1- 2' (1, 4'-biperidin-1'-yl)-1- (phenyl) -ethyl cyclohexanol derivatives as monoamine reuptake modulators for the treatment of visomotor symptoms |
| 04/28/2005 | CA2539811A1 Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| 04/28/2005 | CA2539767A1 1,3-benzoxazolyl derivatives as kinase inhibitors |
| 04/28/2005 | CA2539763A1 Phenylpiperazine cycloalkanol derivatives and methods of their use |
| 04/28/2005 | CA2539761A1 Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| 04/28/2005 | CA2539757A1 Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms |
| 04/28/2005 | CA2539755A1 Alkanol and cycloalkanol-amine derivatives and methods of their use |
| 04/28/2005 | CA2539632A1 Amide or thioamide derivatives and their use in the treatment of pain |
| 04/27/2005 | EP1526177A1 Nucleic acids useful for triggering tumor cell lethality |
| 04/27/2005 | EP1526135A1 Azabenzodiazepines as pde4 inhibitors |
| 04/27/2005 | EP1526134A2 Triazolyl tropane derivatives as ccr5 modulators |
| 04/27/2005 | EP1526133A1 Epothilone derivatives |
| 04/27/2005 | EP1526132A2 Substituted oxazolidinone derivatives and their use as factor xa inhibitors |
| 04/27/2005 | EP1526130A1 Substituted isoquinolines as ultra short acting neuromuscular blockers |
| 04/27/2005 | EP1525884A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525882A1 Administration form comprising an acid-labile active compound |
| 04/27/2005 | EP1525797A2 Synergistic microbicidal combination |
| 04/27/2005 | EP1525549A2 Method for bioequivalence determination using expression profiling |
| 04/27/2005 | EP1525308A2 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 04/27/2005 | EP1525224A1 Hyaluronic acid derivatives |
| 04/27/2005 | EP1525223A2 Ox40 (=cd134) receptor agonists and therapeutic use |
| 04/27/2005 | EP1525215A1 Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy |
| 04/27/2005 | EP1525209A2 1'-, 2'- and 3' -modified nucleoside derivatives for treating flaviviridae infections |
| 04/27/2005 | EP1525204A1 Phenylalanine enamide derivatives |
| 04/27/2005 | EP1525203A1 4-amino-substituted pyrimidine derivatives |
| 04/27/2005 | EP1525201A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 04/27/2005 | EP1525200A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 04/27/2005 | EP1525199A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 04/27/2005 | EP1525198A2 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525194A1 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 04/27/2005 | EP1525193A2 Acylaminothiazole derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525191A2 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 04/27/2005 | EP1525189A1 Crystalline polymorphic and amorphous forms of benazepril hydrochloride |
| 04/27/2005 | EP1525188A2 Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same |
| 04/27/2005 | EP1525186A1 Inhibitors of hcv ns5b polymerase |
| 04/27/2005 | EP1525185A1 Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| 04/27/2005 | EP1525183A1 Inhibitors of hcv ns5b polymerase |
| 04/27/2005 | EP1525180A2 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 04/27/2005 | EP1525177A1 Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
| 04/27/2005 | EP1525030A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 04/27/2005 | EP1525018A1 Medicament dispenser |
| 04/27/2005 | EP1525001A1 Conjugates of porphyrin compounds with chemotherapeutic agents |
| 04/27/2005 | EP1524997A1 Stable liquid parenteral parecoxib formulation |
| 04/27/2005 | EP1524996A2 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 04/27/2005 | EP1524989A2 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 04/27/2005 | EP1524988A1 Use of a proteasome inhibitor in the treatment of fibrotic diseases |
| 04/27/2005 | EP1524985A2 Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated cpg motifs |
| 04/27/2005 | EP1524984A1 Myocardial perfusion imaging using a2a receptor agonists |
| 04/27/2005 | EP1524983A1 COMPOSITION CONTAINING AN ANDROGENOUS 11&bgr;-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION |
| 04/27/2005 | EP1524982A1 Medicament and method for reducing alcohol and/or tobacco consumption |
| 04/27/2005 | EP1524981A1 Sustained release formulations comprising lamotrigine |
| 04/27/2005 | EP1524980A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 04/27/2005 | EP1524978A2 Taste masked sumatriptan tablets and processes for their preparation |
| 04/27/2005 | EP1524977A2 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 04/27/2005 | EP1524976A1 A non-hormonal approach to male contraception |
| 04/27/2005 | EP1524975A1 Improved transdermal delivery system for the administration of rotigotine |
| 04/27/2005 | EP1524974A2 Transcription factor modulating compounds and methods of use thereof |